- Home
- LVLU vs FEMY Comparison
LVLU vs FEMY Comparison
Compare LVLU & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | FEMY |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 37.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LVLU | FEMY |
|---|---|---|
| Price | $15.34 | $0.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $15.00 | $6.83 |
| AVG Volume (30 Days) | 26.9K | ★ 438.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.60 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $315,887,000.00 | $1,629,108.00 |
| Revenue This Year | N/A | $64.02 |
| Revenue Next Year | $2.53 | $147.19 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 51.97 |
| 52 Week Low | $0.22 | $0.31 |
| 52 Week High | $32.32 | $1.76 |
Technical Indicators
Market Signals| Indicator | LVLU | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 44.32 |
| Support Level | $14.18 | $0.33 |
| Resistance Level | $32.32 | $0.57 |
| Average True Range (ATR) | 1.35 | 0.04 |
| MACD | -0.25 | 0.01 |
| Stochastic Oscillator | 48.83 | 50.25 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.